ATE361310T1 - Östronderivate mit zellschützender wirkung - Google Patents

Östronderivate mit zellschützender wirkung

Info

Publication number
ATE361310T1
ATE361310T1 AT01992033T AT01992033T ATE361310T1 AT E361310 T1 ATE361310 T1 AT E361310T1 AT 01992033 T AT01992033 T AT 01992033T AT 01992033 T AT01992033 T AT 01992033T AT E361310 T1 ATE361310 T1 AT E361310T1
Authority
AT
Austria
Prior art keywords
cell
protective effects
estrone derivatives
population
hydroxy
Prior art date
Application number
AT01992033T
Other languages
English (en)
Inventor
Douglas F Covey
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE361310T1 publication Critical patent/ATE361310T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
AT01992033T 2000-11-03 2001-11-05 Östronderivate mit zellschützender wirkung ATE361310T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24579100P 2000-11-03 2000-11-03

Publications (1)

Publication Number Publication Date
ATE361310T1 true ATE361310T1 (de) 2007-05-15

Family

ID=22928089

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01992033T ATE361310T1 (de) 2000-11-03 2001-11-05 Östronderivate mit zellschützender wirkung

Country Status (9)

Country Link
US (3) US6844456B2 (de)
EP (1) EP1330467B1 (de)
JP (1) JP2004518637A (de)
AT (1) ATE361310T1 (de)
AU (1) AU2002232509A1 (de)
CA (1) CA2427817C (de)
DE (1) DE60128251T2 (de)
ES (1) ES2287184T3 (de)
WO (1) WO2002036605A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844456B2 (en) * 2000-11-03 2005-01-18 Washington University Modified, hydroxy-substituted aromatic structures having cytoprotective activity
JP2005515992A (ja) * 2001-12-05 2005-06-02 ミトコー、インク 眼病治療のための多環式フェノール化合物の使用方法
US20070213310A1 (en) 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
US7186707B2 (en) 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
AU2003297739A1 (en) * 2002-12-09 2004-08-30 University Of Florida Prodrugs for use a ophthalmic agents
WO2005116047A2 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
DE102004032674A1 (de) * 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
US7419972B2 (en) 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
US7906210B2 (en) * 2004-10-27 2011-03-15 Nissei Plastic Industrial Co., Ltd. Fibrous nanocarbon and metal composite and a method of manufacturing the same
US20070161611A1 (en) * 2005-12-01 2007-07-12 Dominique Dugourd Polycyclic phenolic compounds and use in treating viral infections
JP4683021B2 (ja) * 2007-08-02 2011-05-11 トヨタ自動車株式会社 燃料電池用電極形成用の触媒担持担体と固体高分子型燃料電池の製造方法
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
CN108976272B (zh) 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US9630986B2 (en) * 2012-12-18 2017-04-25 Washington University Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
PL2986623T3 (pl) 2013-04-17 2019-04-30 Sage Therapeutics Inc 19-nor C3,3-dipodstawione steroidy C21-n-pirazolilowe i sposoby ich stosowania
RU2019126333A (ru) 2013-04-17 2019-10-08 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
RU2696585C2 (ru) 2013-08-23 2019-08-05 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применение
US9425048B2 (en) * 2013-11-06 2016-08-23 Taiwan Semiconductor Manufacturing Co., Ltd. Mechanisms for semiconductor device structure
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
EP3753927B1 (de) 2014-10-16 2023-07-19 Sage Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von störungen des zentralen nervensystems
EP3719029A1 (de) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Zusammensetzungen zur induzierung von sedation
EP3250210B1 (de) 2015-01-26 2020-12-02 Sage Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von störungen des zentralen nervensystems
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
RU2019103590A (ru) 2016-07-11 2021-02-11 Сейдж Терапьютикс, Инк. С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения
PE20230244A1 (es) 2019-05-31 2023-02-07 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1509931A (fr) * 1966-04-29 1968-01-19 Roussel Uclaf Procédé de préparation de composés cétoniques optiquement actifs et produits enrésultant
US3475885A (en) * 1968-05-02 1969-11-04 Millard F Kline Retainer for purification media for gas from sewer line vents
CA942670A (en) 1969-07-28 1974-02-26 Richard A. Edgren Contraceptive compositions
ZA81348B (en) 1980-01-30 1982-02-24 Akzo Nv Novel 17-amino-16-hydroxy steroids of the androstane and oestrane series and derivatives thereof,processes for their preparation and pharmaceutical compositions
US4330540A (en) * 1981-01-29 1982-05-18 Akzo N.V. Ent-16-amino-17-hydroxy-oestra-1,3,5(10)-trienes and derivatives thereof, and pharmaceutical compositions
EP0069424B1 (de) 1981-07-07 1985-05-29 Akzo N.V. Verfahren zur selektiven Reduzierung von einem 14,17-Dioxo-8,14-Seco-Steroid
US4617298A (en) * 1985-10-22 1986-10-14 University Of Florida Method and compositions for weight control
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
US5877169A (en) * 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6197833B1 (en) * 1995-07-24 2001-03-06 Apollo Biopharmaceutics, Inc. Neuroprotective effects of polycyclic phenolic compounds
US6350739B1 (en) 1999-08-11 2002-02-26 University Of Florida Resarch Foundation, Inc. Methods of prevention and treatment of ischemic damage
US5859001A (en) * 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
DE4338316A1 (de) * 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4338314C1 (de) 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
FR2717690B1 (fr) * 1994-03-24 1996-04-26 Roussel Uclaf Application de stéroïdes aromatiques 3 substitués par un aminoalcoxy substitué à l'obtention d'un médicament pour contrôler la stérilité, notamment masculine.
FR2718138B1 (fr) * 1994-04-01 1996-04-26 Roussel Uclaf Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant.
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
CA2227634A1 (en) 1995-07-24 1997-02-06 University Of Florida Research Foundation, Inc. Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells
JP2002501482A (ja) * 1997-01-16 2002-01-15 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド 抗酸化剤との相乗的相互作用を通じて多環式フェノール化合物の細胞保護効果を強化するための組成物
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
AU747807B2 (en) 1997-11-24 2002-05-23 Apollo Biopharmaceutics Inc. Testosterone inhibitors and use for the protection of neurons
US6054446A (en) * 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6245756B1 (en) * 1998-02-27 2001-06-12 Jenapharm Gmbh & Co. Kg Pharmaceutical preparations for treatment of estrogen deficiency in the central nervous system
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
US6265147B1 (en) * 1999-12-01 2001-07-24 The Board Of Trustees Of The Leland Stanford Junior University Method of screening for neuroprotective agents
CN1217995C (zh) * 2000-03-09 2005-09-07 西巴特殊化学品控股有限公司 使用阳离子染料的染发方法
JP3429726B2 (ja) * 2000-04-12 2003-07-22 日本クリニック株式会社 牡蠣肉エキスの製造方法
US6844456B2 (en) * 2000-11-03 2005-01-18 Washington University Modified, hydroxy-substituted aromatic structures having cytoprotective activity
US20070213310A1 (en) * 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
US7026306B2 (en) * 2002-04-01 2006-04-11 University Of Florida Research Foundation, Inc. Steroidal quinols and their use for antioxidant therapy
US7186707B2 (en) * 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
WO2005116047A2 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
US20070161611A1 (en) * 2005-12-01 2007-07-12 Dominique Dugourd Polycyclic phenolic compounds and use in treating viral infections

Also Published As

Publication number Publication date
US20050054624A1 (en) 2005-03-10
WO2002036605A2 (en) 2002-05-10
JP2004518637A (ja) 2004-06-24
US20060009438A2 (en) 2006-01-12
CA2427817A1 (en) 2002-05-10
US9156876B2 (en) 2015-10-13
EP1330467A2 (de) 2003-07-30
CA2427817C (en) 2009-04-14
WO2002036605A9 (en) 2002-10-17
ES2287184T3 (es) 2007-12-16
EP1330467B1 (de) 2007-05-02
DE60128251T2 (de) 2008-01-10
US20110015165A1 (en) 2011-01-20
WO2002036605A3 (en) 2002-07-11
AU2002232509A1 (en) 2002-05-15
US20020103178A1 (en) 2002-08-01
DE60128251D1 (de) 2007-06-14
US6844456B2 (en) 2005-01-18

Similar Documents

Publication Publication Date Title
ATE361310T1 (de) Östronderivate mit zellschützender wirkung
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
AR032471A1 (es) Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos inter
Pardo-Andreu et al. The anti-cancer agent nemorosone is a new potent protonophoric mitochondrial uncoupler
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
ECSP11005768A (es) Derivados de azol-pirimidina condensados
CO5170495A1 (es) Composiciones farmaceuticas para prevencion y tratamiento de enfermedades amiloidogenicas
CY1116520T1 (el) Φαρμακοτεχνικη μορφη fulvestrant
AU2610699A (en) Derivatives of glp-1 analogs
HUP0203304A2 (hu) Prosztatarák megelőzésére szolgáló kemoterápiás módszer és készítmény
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
ATE261974T1 (de) Hoch-lipophile campothecin-derivate
ES2114931T3 (es) Nuevos esteres esteroidales.
NO20004053D0 (no) Glukokortikoid-selektive antiinflammatoriske midler
HUP0102068A2 (hu) Módszer a prosztatarák kemoprevenciós megelőzésére
NO985964D0 (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
UY26920A1 (es) 7 - oxo piridopirimidinas
DE69834271D1 (de) Steroid-3-o-sulfamat-derivate als estronsulfatase-hemmer
ES2180690T3 (es) Preparacion de composiciones que comprenden st1435 para aplicacion topica.
DK1150704T3 (da) Melagatran til behandling af betændelse
NO944214L (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
PA8495001A1 (es) Nuevas formas cristalinas de un antibiotico macrolido.
SE0002211D0 (sv) Methods and compositions for prevention of myopia
ATE49216T1 (de) Substituierte benzoatesterderivate als estrogen- wirkstoffvorlaeufer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1330467

Country of ref document: EP